|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TAF3 |
Gene summary for TAF3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TAF3 | Gene ID | 83860 |
| Gene name | TATA-box binding protein associated factor 3 | |
| Gene Alias | TAF140 | |
| Cytomap | 10p14 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q5VWG9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 83860 | TAF3 | CCI_2 | Human | Cervix | CC | 4.29e-10 | 1.15e+00 | 0.5249 |
| 83860 | TAF3 | CCI_3 | Human | Cervix | CC | 1.90e-05 | 6.18e-01 | 0.516 |
| 83860 | TAF3 | LZE4T | Human | Esophagus | ESCC | 3.05e-08 | 2.71e-01 | 0.0811 |
| 83860 | TAF3 | LZE5T | Human | Esophagus | ESCC | 2.84e-03 | 1.69e-01 | 0.0514 |
| 83860 | TAF3 | LZE7T | Human | Esophagus | ESCC | 4.08e-05 | 2.01e-01 | 0.0667 |
| 83860 | TAF3 | LZE8T | Human | Esophagus | ESCC | 3.93e-02 | 6.15e-02 | 0.067 |
| 83860 | TAF3 | LZE22T | Human | Esophagus | ESCC | 2.02e-03 | 1.69e-01 | 0.068 |
| 83860 | TAF3 | LZE24T | Human | Esophagus | ESCC | 5.29e-15 | 3.38e-01 | 0.0596 |
| 83860 | TAF3 | LZE21T | Human | Esophagus | ESCC | 1.65e-04 | 2.39e-01 | 0.0655 |
| 83860 | TAF3 | LZE6T | Human | Esophagus | ESCC | 3.99e-04 | 1.05e-01 | 0.0845 |
| 83860 | TAF3 | P1T-E | Human | Esophagus | ESCC | 1.78e-02 | 2.65e-01 | 0.0875 |
| 83860 | TAF3 | P2T-E | Human | Esophagus | ESCC | 7.28e-25 | 3.67e-01 | 0.1177 |
| 83860 | TAF3 | P4T-E | Human | Esophagus | ESCC | 2.61e-21 | 3.77e-01 | 0.1323 |
| 83860 | TAF3 | P5T-E | Human | Esophagus | ESCC | 2.10e-18 | 2.34e-01 | 0.1327 |
| 83860 | TAF3 | P8T-E | Human | Esophagus | ESCC | 4.47e-11 | 2.59e-01 | 0.0889 |
| 83860 | TAF3 | P9T-E | Human | Esophagus | ESCC | 6.35e-08 | 2.01e-01 | 0.1131 |
| 83860 | TAF3 | P10T-E | Human | Esophagus | ESCC | 4.84e-13 | 1.61e-01 | 0.116 |
| 83860 | TAF3 | P11T-E | Human | Esophagus | ESCC | 9.29e-08 | 1.83e-01 | 0.1426 |
| 83860 | TAF3 | P12T-E | Human | Esophagus | ESCC | 2.49e-20 | 5.30e-01 | 0.1122 |
| 83860 | TAF3 | P15T-E | Human | Esophagus | ESCC | 2.89e-18 | 3.32e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
| GO:005165110 | Cervix | CC | maintenance of location in cell | 55/2311 | 214/18723 | 6.63e-08 | 3.85e-06 | 55 |
| GO:00345048 | Cervix | CC | protein localization to nucleus | 68/2311 | 290/18723 | 9.91e-08 | 5.25e-06 | 68 |
| GO:00510904 | Cervix | CC | regulation of DNA-binding transcription factor activity | 87/2311 | 440/18723 | 4.85e-06 | 1.22e-04 | 87 |
| GO:00325077 | Cervix | CC | maintenance of protein location in cell | 21/2311 | 65/18723 | 2.03e-05 | 3.71e-04 | 21 |
| GO:004518510 | Cervix | CC | maintenance of protein location | 26/2311 | 94/18723 | 4.85e-05 | 7.34e-04 | 26 |
| GO:00725955 | Cervix | CC | maintenance of protein localization in organelle | 14/2311 | 42/18723 | 3.32e-04 | 3.49e-03 | 14 |
| GO:00514571 | Cervix | CC | maintenance of protein location in nucleus | 8/2311 | 23/18723 | 4.70e-03 | 2.82e-02 | 8 |
| GO:003450418 | Esophagus | ESCC | protein localization to nucleus | 211/8552 | 290/18723 | 4.06e-21 | 6.60e-19 | 211 |
| GO:0045185111 | Esophagus | ESCC | maintenance of protein location | 71/8552 | 94/18723 | 3.41e-09 | 7.24e-08 | 71 |
| GO:0051235110 | Esophagus | ESCC | maintenance of location | 200/8552 | 327/18723 | 1.01e-08 | 2.02e-07 | 200 |
| GO:0032507110 | Esophagus | ESCC | maintenance of protein location in cell | 52/8552 | 65/18723 | 1.41e-08 | 2.77e-07 | 52 |
| GO:007259517 | Esophagus | ESCC | maintenance of protein localization in organelle | 36/8552 | 42/18723 | 8.46e-08 | 1.44e-06 | 36 |
| GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
| GO:005145712 | Esophagus | ESCC | maintenance of protein location in nucleus | 20/8552 | 23/18723 | 4.97e-05 | 3.86e-04 | 20 |
| GO:0051651111 | Esophagus | ESCC | maintenance of location in cell | 126/8552 | 214/18723 | 6.57e-05 | 5.00e-04 | 126 |
| GO:00434332 | Esophagus | ESCC | negative regulation of DNA-binding transcription factor activity | 103/8552 | 185/18723 | 3.86e-03 | 1.57e-02 | 103 |
| GO:003450411 | Liver | Cirrhotic | protein localization to nucleus | 113/4634 | 290/18723 | 5.00e-08 | 1.58e-06 | 113 |
| GO:00451857 | Liver | Cirrhotic | maintenance of protein location | 46/4634 | 94/18723 | 3.31e-07 | 7.90e-06 | 46 |
| GO:00325074 | Liver | Cirrhotic | maintenance of protein location in cell | 35/4634 | 65/18723 | 4.60e-07 | 1.05e-05 | 35 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa030222 | Esophagus | ESCC | Basal transcription factors | 35/4205 | 45/8465 | 1.01e-04 | 4.06e-04 | 2.08e-04 | 35 |
| hsa0302211 | Esophagus | ESCC | Basal transcription factors | 35/4205 | 45/8465 | 1.01e-04 | 4.06e-04 | 2.08e-04 | 35 |
| hsa03022 | Oral cavity | OSCC | Basal transcription factors | 28/3704 | 45/8465 | 9.53e-03 | 2.11e-02 | 1.08e-02 | 28 |
| hsa030221 | Oral cavity | OSCC | Basal transcription factors | 28/3704 | 45/8465 | 9.53e-03 | 2.11e-02 | 1.08e-02 | 28 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TAF3 | SNV | Missense_Mutation | c.1171N>G | p.Ile391Val | p.I391V | Q5VWG9 | protein_coding | deleterious(0.02) | benign(0.371) | TCGA-BH-A1FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TAF3 | SNV | Missense_Mutation | c.1553C>T | p.Ser518Phe | p.S518F | Q5VWG9 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.483) | TCGA-E9-A1NI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
| TAF3 | deletion | Frame_Shift_Del | c.627_630delATTG | p.Leu210LysfsTer9 | p.L210Kfs*9 | Q5VWG9 | protein_coding | TCGA-AN-A0XS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |||
| TAF3 | insertion | Frame_Shift_Ins | novel | c.1484_1485insTTACTTTT | p.Ser496TyrfsTer29 | p.S496Yfs*29 | Q5VWG9 | protein_coding | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| TAF3 | deletion | Frame_Shift_Del | novel | c.1305delA | p.Ala436LeufsTer86 | p.A436Lfs*86 | Q5VWG9 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| TAF3 | SNV | Missense_Mutation | rs778952496 | c.962C>T | p.Pro321Leu | p.P321L | Q5VWG9 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TAF3 | SNV | Missense_Mutation | novel | c.2681N>T | p.Cys894Phe | p.C894F | Q5VWG9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| TAF3 | SNV | Missense_Mutation | novel | c.151C>T | p.Arg51Trp | p.R51W | Q5VWG9 | protein_coding | deleterious(0) | probably_damaging(0.92) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TAF3 | insertion | Frame_Shift_Ins | novel | c.1048_1049insA | p.Ile352AsnfsTer3 | p.I352Nfs*3 | Q5VWG9 | protein_coding | TCGA-VS-A9UJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | ||
| TAF3 | SNV | Missense_Mutation | rs201464808 | c.865N>A | p.Ala289Thr | p.A289T | Q5VWG9 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |